Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCAT 2023 | Treatment of patients with SCD who are not eligible for transfusion

Lewis Hsu, MD, PhD, University of Illinois at Chicago, Chicago, IL, discusses how clinicians can manage and treat patients with sickle cell disease (SCD) who are ineligible for transfusion and briefly outlines the aims of some current clinical trials in SCD treatment. This interview was recorded at the 18th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) 2023, held in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.